Advanced search    

Search: authors:"Koichi Takayama"

16 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial

Purpose Cancer cachexia is characterized by decreased body weight (mainly lean body mass [LBM]) and negatively impacts quality of life (QOL) and prognosis. Anamorelin (ONO-7643) is a novel selective ghrelin receptor agonist under development for treating cancer cachexia. Methods In this double-blind, exploratory phase 2 trial, we examined the efficacy and safety of anamorelin in...

Longitudinal assessment of pain management with the pain management index in cancer outpatients receiving chemotherapy

baseline and follow-up, respectively, with ∼14% of patients having moderate or severe pain at each assessment. Totals of 365 Koichi Takayama patients (69.7%) at baseline and 320 patients (61.1%) at follow

Longitudinal assessment of pain management with the pain management index in cancer outpatients receiving chemotherapy

, respectively, with ∼14% of patients having moderate or severe pain at each assessment. Totals of 365 Koichi Takayama patients (69.7%) at baseline and 320 patients (61.1%) at follow-up reported pain or were

Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer

Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer Eiji Iwama,1,2 Isamu Okamoto,3 Taishi Harada,2 Koichi Takayama,2 Yoichi

Changes in sebum levels and the development of acneiform rash in patients with non–small cell lung cancer after treatment with EGFR inhibitors

Changes in sebum levels and the development of acneiform rash in patients with non–small cell lung cancer after treatment with EGFR inhibitors Takeshi Nakahara,1,2 Yoichi Moroi,2 Koichi Takayama,3 ... OncoTargets and Therapy changes in sebum levels and the development of acneiform rash in patients with non-small cell lung cancer after treatment with egFr inhibitors Yoichi Moroi 1 3 Koichi

Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer

Koichi Takayama,1 Shunichi Sugawara,2 Yasuo Saijo,3 Makoto Maemondo,4 Atsushi Sato,5 Shinzo Takamori,6 Taishi Harada,7 Tetsuro Sasada,8 Tatsuyuki Kakuma,9 Junji Kishimoto,10 Akira Yamada,11 Masanori ... , Kurume, Japan Received 25 January 2016; Accepted 7 April 2016 Academic Editor: Senthamil Selvan Copyright © 2016 Koichi Takayama et al. This is an open access article distributed under the Creative

Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer

Koichi Takayama,1 Shunichi Sugawara,2 Yasuo Saijo,3 Makoto Maemondo,4 Atsushi Sato,5 Shinzo Takamori,6 Taishi Harada,7 Tetsuro Sasada,8 Tatsuyuki Kakuma,9 Junji Kishimoto,10 Akira Yamada,11 Masanori ... , Kurume, Japan Received 25 January 2016; Accepted 7 April 2016 Academic Editor: Senthamil Selvan Copyright © 2016 Koichi Takayama et al. This is an open access article distributed under the Creative

Methylenetetrahydrofolate reductase polymorphisms and interaction with smoking and alcohol consumption in lung cancer risk: a case-control study in a Japanese population

Background Cigarette smoking is an established risk factor of lung cancer development while the current epidemiological evidence is suggestive of an increased lung cancer risk associated with alcohol consumption. Dietary folate, which is present in a wide range of fresh fruits and vegetables, may be a micronutrient that has a beneficial impact on lung carcinogenesis...

Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression

Purpose Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), and bevacizumab, an anti-vascular endothelial growth factor (VEGF) agent, are promising therapies for advanced non-small cell lung cancer (NSCLC). Our study was aimed to determine whether there were conditions under which the addition of bevacizumab would enhance the antitumor activity...

Lung Cancer Risk and Genetic Polymorphisms in DNA Repair Pathways: A Meta-Analysis

Genetic variations in DNA repair genes are thought to modulate DNA repair capacity and are suggested to be related to lung cancer risk. We conducted a meta-analysis of epidemiologic studies on the association between genetic polymorphisms in both base excision repair and nucleotide excision repair pathways, and lung cancer. We found xeroderma pigmentosum complementation group A...

Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients—Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study

) identification number: UMIN000003630. Conflict of interest Koichi Takayama received honoraria from Chugai Pharmaceutical, Eli Lilly Japan, Pfizer Japan, and AstraZeneca; advisory fees from Kyushu Research Support

Effect of Sunitinib Combined with Ionizing Radiation on Endothelial Cells

Hai-Ping ZHANG Koichi TAKAYAMA Bo SU Xiao-dong JIAO Rui LI Jie-Jun WANG Sunitinib/Ionizing radiation/Caspase-3/PI3K/Akt/Endothelial cell. The aims of present study were to evaluate the efficacy of

Systemic Therapy for Cervical Cancer with Potentially Regulatable Oncolytic Adenoviruses

Clinical trials have confirmed the safety of selectively oncolytic adenoviruses for treatment of advanced cancers. However, increasingly effective viruses could result in more toxicity and therefore it would be useful if replication could be abrogated if necessary. We analyzed viruses containing the cyclooxygenase-2 (Cox-2) or vascular endothelial growth factor (VEGF) promoter...

Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor

We have shown that a soluble receptor for vascular endothelial growth factor (sVEGFR), which adsorbs VEGF and may function as a dominant-negative receptor, suppresses tumor angiogenesis and enhances apoptosis of cancer cells, thereby inhibiting tumor growth [Cancer Res 60 (2000) 2169–2177]. In the present study, using as many as 11 cancer cell lines, we tested two hypotheses: (a...

Infectivity enhanced, hTERT promoter-based conditionally replicative adenoviruses are useful for SCLC treatment

Treatment of advanced small-cell lung cancer (SCLC) remains one of the major challenges in current medicine because of the high morbidity and mortality of the disease. Advanced stage lung cancer is refractory to conventional therapies and it also has an extremely poor prognosis. As a result, new therapeutic approaches are needed. Telomere maintenance to the regulation of...

Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells

The aim of the present study is to identify the optimal anticancer agents for use in combination with gene therapy using wild-type (wt) p53 gene transfer. We used adenoviral vectors expressing human wt p53 (AdCAp53) and investigated the effects of wt p53 gene transfer in combination with 12 anticancer agents on a human pulmonary squamous cell carcinoma cell line, NCI-H157, and a...